Roche Sees Oncology Access Programs Key To Growth
This article was originally published in PharmAsia News
Against a backdrop of increasing payer scrutiny over the high price tags of new cancer treatments, Roche is looking at two main strategies to ensure access to its therapies in the sector, covering both developed countries and emerging markets.
You may also be interested in...
A new report on China’s pharma innovation ecosystem paints a grim picture of negative market returns for many novel drugs despite shortened review timelines and government calls to encourage innovation.
China was a focus of discussions at the 2020 J.P. Morgan Healthcare Conference, as a Phase One trade agreement was signed to end a 17-month dispute with the US. Patent linkage and IP protection enforcement are also being closely watched, while Chinese firms including BeiGene continue to make strides in oncology deal-making.
2019 will be remembered as a banner year for international drug makers as many grew at phenomenal rates in China, despite expansion of the “4+7” centralized procurement scheme and steep price cuts in exchange for reimbursement. As the government continues to emphasize affordability for cancer drugs and major anti-infectives, competition is heating up quickly and immune-oncology alone has seen six PD-1s elbowing each other for market share.